Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

NCT05346861 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05346861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05346861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Unknown status
Start date
September 15, 2021
Completion date
October 31, 2024
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, metastatic breast cancer